GlassScriptPhysician profile
Antonio Cruz
NPI 1063603553
$3,324.57
in general payments reported to CMS, 2019-2025
24 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $510 · 2021: $228 · 2022: $227 · 2023: $843 · 2024: $477 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,770 · Grant: $30.00 · Education: $11.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,769.92 |
| Grant | $30.00 |
| Education | $11.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,066.91 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Janssen Biotech, INC. | $391.77 | 2019-2025 | Tremfya, Remicade, Simponi |
| Galderma Laboratories, L.P. | $342.17 | 2019-2025 | Nemluvio |
| Leo Pharma INC. | $241.89 | 2019-2023 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $157.54 | 2019-2021 | |
| Amgen INC. | $146.23 | 2020-2022 | |
| Merz North America, INC. | $127.28 | 2019-2020 | |
| Dermavant Sciences, INC. | $120.12 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $114.93 | 2022-2023 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $82.72 | 2020-2024 | |
| Genzyme Corporation | $75.51 | 2024-2025 | |
| Osiris Therapeutics INC. | $65.91 | 2019 | |
| Incyte Corporation | $64.16 | 2023 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $59.04 | 2023-2025 | Dupixent |
| Genentech USA, INC. | $58.97 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $48.55 | 2019 | |
| Lilly USA, LLC | $35.25 | 2019-2023 | Olumiant |
| Mayne Pharma Commercial LLC | $26.30 | 2019 | |
| Organon LLC | $21.49 | 2025 | Hadlima |
| Musculoskeletal Transplant Foundation INC. | $17.20 | 2019 | |
| Almirall LLC | $17.01 | 2019 | |
| Ucb, INC. | $16.28 | 2020 | |
| Allergan, INC. | $14.81 | 2022 | |
| Merck Sharp & Dohme LLC | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.